Kalaris Therapeutics (KLRS) Assets Average (2020 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Assets Average of $115.8 million for Q1 2026, up 111.93% year-over-year from $54.6 million in Q1 2025, and up 14.11% quarter-over-quarter from $101.5 million in Q4 2025.
Kalaris Therapeutics (KLRS) Assets Average (2020 - 2026) Analysis & Trends
Kalaris Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $115.8 million for Q1 2026.
- In Q1 2026, Assets Average rose 111.93% year-over-year to $115.8 million; the TTM figure through Mar 2026 stood at $115.8 million (up 111.93% YoY), while the FY2025 annual figure was $63.9 million, down 35.06% from the prior year.
- Assets Average for Q1 2026 stood at $115.8 million, up from $101.5 million in the prior quarter.
- The five-year high for Assets Average was $285.4 million in Q4 2022, with the low at $54.6 million in Q1 2025.
- The 5-year median for Assets Average is $167.5 million (2024), against an average of $174.6 million.
- The sharpest annual moves came in 2024 and 2026: Assets Average plunged 70.69% in 2024, then jumped 111.93% in 2026.
- Kalaris Therapeutics' Assets Average stood at $285.4 million in 2022, then decreased by 23.07% to $219.6 million in 2023, then slumped by 70.69% to $64.3 million in 2024, then surged by 57.67% to $101.5 million in 2025, then rose by 14.11% to $115.8 million in 2026.
- Business Quant data shows KLRS's Assets Average at $115.8 million in Q1 2026, $101.5 million in Q4 2025, and $87.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 19.82 Bn |
| 10 | Kalaris Therapeutics | 99.71 Mn | 99.71 Mn | - | 104.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104.67 Mn |
| Mar 31, 2026 | 115.77 Mn |
| Dec 31, 2025 | 101.46 Mn |
| Sep 30, 2025 | 87.01 Mn |
| Jun 30, 2025 | 97.97 Mn |
| Mar 31, 2025 | 54.63 Mn |
| Dec 31, 2024 | 64.35 Mn |
| Sep 30, 2024 | 126.76 Mn |
| Jun 30, 2024 | 137.57 Mn |
| Mar 31, 2024 | 167.47 Mn |
| Dec 31, 2023 | 219.55 Mn |
| Sep 30, 2023 | 265.50 Mn |
| Jun 30, 2023 | 263.37 Mn |
| Mar 31, 2023 | 260.56 Mn |
| Dec 31, 2022 | 285.39 Mn |
| Sep 30, 2022 | 246.85 Mn |
| Jun 30, 2022 | 215.54 Mn |
| Mar 31, 2022 | 258.84 Mn |
| Dec 31, 2021 | 301.56 Mn |
| Sep 30, 2021 | 322.02 Mn |